Kyndryl (KD) Q4 2026 Earnings Call Transcript

Kyndryl reported fiscal 2026 revenue of $15.1 billion, flat year over year and down 3% in constant currency, but delivered $2.7 billion of adjusted EBITDA, $581 million of adjusted pretax income, and $406 million of free cash flow, all with margin expansion. Consult revenue grew double digits for a third straight year and hyperscaler-related revenue rose 59% to $1.9 billion, while management guided fiscal 2027 revenue to flat to down 2% in constant currency and adjusted pretax income to $600 million to $700 million. The company also highlighted $1 billion of annualized savings, $304 million of buybacks, and ongoing remediation of material weaknesses, but IBM-related headwinds and elongated sales cycles remain a drag.

Analysis

Kyndryl’s setup is less about headline revenue and more about mix transition: the business is proving it can convert slower top-line growth into expanding margins and cash despite IBM-related attrition. The market is still underestimating the lag between signings and revenue, which matters because the company is increasingly winning higher-margin consult, alliance, and new-scope work that should show up in P&L with a delay; that creates a near-term revenue overhang but a cleaner FY28 earnings path. The key second-order effect is that IBM headwinds appear structurally separate from operating performance, so the stock can de-rate on low growth while fundamentals improve underneath.

The operational signal that matters most is the acceleration in new-scope wins and the embedding of AI into delivery. Faster incident resolution and root-cause analysis are not just cost savings; they improve service levels enough to support pricing discipline and expand Kyndryl’s share of wallet in regulated, sovereignty-sensitive environments where switching costs are rising. That dynamic can make the company more resilient than the market expects, but it also creates a longer-duration story: this is a 6-18 month execution narrative, not a next-quarter re-rating catalyst.

The main risk is that investors treat the revenue guide as a ceiling rather than a bridge, and that is where the short side likely gets crowded. If IBM purchasing behavior stabilizes even modestly, or if large European deals start converting faster as regulatory clarity improves, the stock could rerate sharply because the profit and cash flow targets already assume most of the pain. Conversely, if deal cycles stay elongated and the material weaknesses linger into the next 10-K, the market will keep discounting the multiple regardless of margin progress.

Key Decisions for Investors

• Go long KD on weakness after the post-earnings digestion period, targeting a 3-6 month horizon; use a starter position and add only if backlog/signings conversion remains intact, because the downside is mostly sentiment while upside comes from FY27/FY28 margin realization.
• Pair trade: long KD / short IBM for 3-6 months. The thesis is that IBM’s partner-channel behavior is creating a revenue drag for KD while IBM absorbs the strategic mix risk; if IBM content normalizes, KD’s revenue surprise upside is larger than IBM’s downside from the same channel friction.
• Buy KD call spreads 6-9 months out rather than outright stock if you want exposure to a rerating from cash flow and buybacks; the structure benefits if the market starts pricing FY28 free cash flow before revenue growth re-accelerates.
• Avoid shorting KD on the guide alone unless you have a catalyst on controls or deal slippage; the better short would be a tactical trade after any rally tied to IBM-relief hopes, because the stock could mean-revert if management simply demonstrates steady conversion.
• Monitor for a long entry trigger in the next 60-90 days: any evidence that new-scope consult bookings are converting faster than expected would be the clearest sign that the market is over-discounting the low-growth narrative.